Scarica l'app Stockscreener
4.20
1.45%
0.06
Dopo l'orario di chiusura:
4.18
-0.02
-0.48%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ACRS Giù?
Forum
Previsione
Precedente Chiudi:
$4.14
Aprire:
$4.05
Volume 24 ore:
937.47K
Relative Volume:
0.42
Capitalizzazione di mercato:
$508.57M
Reddito:
$7.83M
Utile/perdita netta:
$-64.92M
Rapporto P/E:
-7.929
EPS:
-0.5297
Flusso di cassa netto:
$-47.22M
1 W Prestazione:
+19.32%
1M Prestazione:
+37.70%
6M Prestazione:
+128.26%
1 anno Prestazione:
+172.73%
Intervallo 1D:
$4.0204
$4.22
Intervallo di 1 settimana:
$3.345
$4.22
Portata 52W:
$1.05
$4.89
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
Nome
Aclaris Therapeutics Inc
Settore
Industria
Telefono
484-324-7933
Indirizzo
701 LEE ROAD, WAYNE, PA
Compare ACRS vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
4.20 | 508.57M | 7.83M | -64.92M | -47.22M | -0.5297 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-10 | Ripresa | Piper Sandler | Overweight |
| 2025-05-28 | Iniziato | Wedbush | Outperform |
| 2025-03-18 | Ripresa | Cantor Fitzgerald | Overweight |
| 2024-12-23 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-11-20 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-19 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2024-11-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-11-19 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-11-18 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-01-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-11-13 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-10-03 | Iniziato | Evercore ISI | Outperform |
| 2022-12-14 | Iniziato | Stifel | Buy |
| 2022-12-01 | Iniziato | Goldman | Buy |
| 2022-10-06 | Iniziato | BTIG Research | Buy |
| 2021-07-23 | Ripresa | Jefferies | Buy |
| 2021-06-15 | Iniziato | Piper Sandler | Overweight |
| 2021-04-21 | Iniziato | H.C. Wainwright | Buy |
| 2019-10-22 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-06 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-27 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2019-05-06 | Iniziato | SVB Leerink | Outperform |
| 2018-03-28 | Ripresa | Leerink Partners | Outperform |
| 2018-02-09 | Iniziato | Guggenheim | Buy |
| 2017-06-16 | Iniziato | Cantor Fitzgerald | Overweight |
| 2016-11-29 | Iniziato | Leerink Partners | Outperform |
| 2016-09-30 | Iniziato | JMP Securities | Mkt Outperform |
| 2016-06-10 | Iniziato | Guggenheim | Buy |
| 2015-11-02 | Iniziato | Citigroup | Buy |
| 2015-11-02 | Iniziato | Jefferies | Buy |
Mostra tutto
Aclaris Therapeutics Inc Borsa (ACRS) Ultime notizie
ACRS PE Ratio & Valuation, Is ACRS Overvalued - Intellectia AI
Aclaris Therapeutics (NASDAQ:ACRS) Upgraded at Wall Street Zen - MarketBeat
Aug Macro: Is Bit Digital Inc a top pick in the sector2026 Reactions & Consistent Growth Equity Picks - baoquankhu1.vn
Aclaris Therapeutics (NASDAQ:ACRS) Trading Up 10.2%What's Next? - MarketBeat
Aclaris to present phase 2a ATI-2138 data at dermatology meeting - MSN
Aclaris completes enrollment in phase 2 trial of Bosakitug for atopic dermatitis - MSN
Aclaris Therapeutics' (ACRS) Outperform Rating Reaffirmed at Wedbush - MarketBeat
Aclaris Therapeutics (NASDAQ:ACRS) Shares Pass Below 50 Day Moving AverageShould You Sell? - MarketBeat
ACRS Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Analyst Upgrade: Why is Aclaris Therapeutics Inc stock going upMarket Risk Report & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Market Wrap: Why is Aclaris Therapeutics Inc stock going up2026 Retail & Weekly Top Gainers Alerts - baoquankhu1.vn
Common Warts Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Verrica Pharma, Kino Pharma, Iwaki Pharma, Aclaris Therapeutics, KinoPharma - Barchart
Aclaris Therapeutics Reports Positive Phase 2a Trial Results for ATI-2138 in Atopic Dermatitis, Showing Significant Improvements in Disease Severity and Quality of Life - Quiver Quantitative
Experimental eczema pill cut disease severity 77% in 12-week trial - Stock Titan
Aclaris to Present Phase 2a ATI-2138 Data at Dermatology Meeting - MyChesCo
Vanguard (ACRS) Amends Schedule 13G; Reports 0 Shares After Realignment - Stock Titan
Profound Medical (PROF) Surges 13.0%: Is This an Indication of Further Gains? - Yahoo Finance Singapore
Published on: 2026-03-26 16:32:45 - baoquankhu1.vn
Aclaris Completes Enrollment in Phase 2 Trial of Bosakitug for Atopic Dermatitis - MyChesCo
Q1 EPS Estimate for Aclaris Therapeutics Raised by Analyst - MarketBeat
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Beats Revenue Estimates - MSN
Published on: 2026-03-22 04:18:49 - baoquankhu1.vn
Aclaris Therapeutics to present ATI-2138 atopic dermatitis trial data - Investing.com
Deep Track Capital, LP Acquires Significant Stake in Aclaris Therapeutics Inc - GuruFocus
Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting - The Manila Times
Aclaris Therapeutics Announces ePoster Presentation on Phase 2a Trial Results of ATI-2138 for Moderate-to-Severe Atopic Dermatitis at AAD Annual Meeting 2026 - Quiver Quantitative
Aclaris Therapeutics Announces Poster on Results from Phase - GlobeNewswire
Aclaris stock maintained at Buy by H.C. Wainwright on trial progress - Investing.com Canada
Aclaris Therapeutics (NASDAQ:ACRS) Receives Buy Rating from HC Wainwright - MarketBeat
Aclaris completes enrollment in atopic dermatitis trial By Investing.com - Investing.com Canada
HC Wainwright Has Positive Forecast for ACRS FY2026 Earnings - MarketBeat
Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis - Bitget
Aclaris Therapeutics completes enrollment in phase 2 trial of bosakitug (ATI-045) in atopic dermatitis - marketscreener.com
Aclaris Therapeutics Completes Enrollment In Phase 2 Trial Of Bosakitug (Ati-045) In Atopic Dermatitis - TradingView
Aclaris Therapeutics Completes Patient Enrollment in Phase 2 Trial for Bosakitug in Atopic Dermatitis, Top Line Results Expected Q4 2026 - quiverquant.com
109-patient atopic dermatitis trial filled; results coming Q4 2026 - Stock Titan
Deep Track entities hold 9.35M Aclaris shares (ACRS) — 7.01% stake - Stock Titan
Research Analysts Offer Predictions for ACRS FY2027 Earnings - MarketBeat
Analysts Offer Insights on Healthcare Companies: Aclaris Therapeutics (ACRS) and Plus Therapeutics (PSTV) - The Globe and Mail
Aclaris Therapeutics stock rating reiterated at Buy by H.C. Wainwright - Investing.com Canada
Aclaris to Host 2025 R&D Day in New York to Spotlight Immuno-Inflammatory Pipeline - MSN
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Aclaris Therapeutics to Present New Data on Atopic Dermatitis Drug at EADV Congress - MSN
Aclaris Therapeutics Raises $20 Million in Equity Financing - The Globe and Mail
Helus Pharma taps veteran Jill Conwell to steer people strategy for growth - Stock Titan
Aclaris Therapeutics, Inc. Files Form 8-K with SEC Detailing Company Information as of March 10, 2026 - Minichart
Aclaris Therapeutics sells 5.7M shares for $20.0M to institutional buyers - TradingView
Aclaris Therapeutics (NASDAQ: ACRS) sells 5.7M shares to raise $20M - Stock Titan
Aclaris Therapeutics Inc Azioni (ACRS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):